Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
about
The update of prostatic ductal adenocarcinomaNovel biomarkers for prostate cancer including noncoding transcripts.Proteomics in prostate cancer biomarker discovery.Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigenProlonged remission of fulminant castrate-resistant prostate cancer: a case report.Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital.Low detectable prostate specific antigen after radical prostatectomy--treat or watch?Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.Beyond PSA: the next generation of prostate cancer biomarkers.Review of small cell carcinomas of the prostate.The utility of prostate-specific antigen in the management of advanced prostate cancer.Molecular pathology and prostate cancer therapeutics: from biology to bedside.Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram.Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen.Ductal Adenocarcinoma of the Prostate: A Case Report.Unilateral testicular metastasis of low PSA level prostatic adenocarcinoma.Penile Metastases of Recurrent Prostatic Adenocarcinoma without PSA Level Increase: A Case Report.Correlation between postoperative prostate-specific antigen and biochemical recurrence in positive surgical margin patients: Single surgeon series.Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy.Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy.[Non-PSA-expressing, solid, and growing mass of the prostate].Sarcomatoid carcinoma of the prostate:ERGfluorescencein-situhybridization confirms epithelial origin
P2860
Q26752939-BB9959A7-7FF0-4790-9966-07C18D3C7593Q33515231-DD949BA4-B3BF-41F6-8C41-93D74960D2BDQ34096086-7E9C142D-2BC7-4750-82FF-4DC92A79CFB0Q35034245-FA998634-9BAB-4E7F-8BC3-C04FB0E7F55CQ35490140-1B7E8F32-972F-4C2E-A0DE-41E7B050DEABQ36051783-EE2B0AED-FC79-44F8-AEA7-6929022B7A5DQ36058911-C8889644-4289-4BB0-9682-280223C85ACDQ36100502-654F7E5B-8F98-4773-86B8-D33CED75259EQ36502875-C45D34CF-485A-4540-9664-2BDA84996BDBQ37238101-6E9A6B85-B5DC-44B7-B750-8C410B9A9EC5Q37960020-6B7412E8-7277-49AD-846F-E7CB8C85F96AQ38119260-869EF19C-6A20-4DD8-B7C2-F139165E0FD4Q38151036-D76AB8DD-772B-425D-B39B-BE7049731280Q38209356-12748A4C-E8DA-4DB6-ABB0-48C609AACC37Q39476138-655EE005-1B7F-4215-9D73-76A8639EC232Q40666732-6463C7DC-5EC4-4EC0-A7E0-400059768F96Q40835366-5A216B5F-52B8-4C69-A230-73C9C808F133Q41004448-C1FCDF6B-D5AE-468C-97CE-2231B7AF1BA0Q41896531-9217F4F2-7CA7-4769-A5F0-A02C0973009CQ42062124-780F2191-0BAF-4DAA-9182-CA81F4375F25Q45024800-8E3C346C-9B64-4508-968E-222C37870122Q47122203-A8A67B4D-3797-472A-8B56-97A01F46D33DQ52836910-967FCC8F-2981-4CD4-AC83-297E2ACEC905Q57693868-D5C44C1A-B8FC-42C6-9F14-FEDFF9011BAF
P2860
Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Prostate cancer progression in ...... ostate-specific antigen level.
@en
Prostate cancer progression in ...... ostate-specific antigen level.
@nl
type
label
Prostate cancer progression in ...... ostate-specific antigen level.
@en
Prostate cancer progression in ...... ostate-specific antigen level.
@nl
prefLabel
Prostate cancer progression in ...... ostate-specific antigen level.
@en
Prostate cancer progression in ...... ostate-specific antigen level.
@nl
P2093
P356
P1433
P1476
Prostate cancer progression in ...... ostate-specific antigen level.
@en
P2093
Curtis A Pettaway
Dan Leibovici
Kate Hitzhusen
Louis L Pisters
Philippe E Spiess
Randall E Millikan
Shi-Ming Tu
P304
P356
10.1002/CNCR.22372
P407
P577
2007-01-01T00:00:00Z